Mohammad AskarPublic working copy · medical review pending

Clinical communication · 140

Clinical communication: clarify, examine and agree the next step

Use simple patient language and precise documentation without inventing findings from a shorthand note or a damaged quotation.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Begin with the patient’s concern, translate descriptions into questions rather than diagnoses, document what was actually examined and confirm the treatment plan through teach-back. Reassurance must include its limits and a clear safety net.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Open the consultation and clarify the symptom

Welcome the patient and ask an open question such as “What has brought you here?” or “What concerns you most?” Clarify onset, course, laterality and impact on reading, work or daily activities; ask when medicines began and whether they are used as prescribed. Ask about driving and travel before dilation and arrange an appropriate plan rather than assuming the patient can drive home immediately. 1 2 6

A description of pressure or headache does not measure intraocular pressure. Black spots may be floaters; flashes or flicker, blurred vision, reading difficulty and unstable television images need their own timing and associated-symptom questions. Preserve the original anecdote of 3 right-sided flashes as an example of a reported symptom, not a diagnostic threshold. Ask separately about burning or sand sensation, dryness, overnight discharge/stickiness and light sensitivity. 1

The original contains garbled phrases presented as authentic dialogue, including “sand in the diver” and a mistaken word for optic-disc cupping. No source recording authenticates these quotations. Use the edited examples as teaching language, preserve the original wording in the archive and ask the patient to clarify rather than turning a guessed transcription into a clinical fact. 1

02Give one clear examination instruction at a time

Explain the device, invite the patient to sit, then guide chin, forehead and straight-ahead fixation without forcing an uncomfortable position. For eye movements, give a clear target and direct up, right, left or down as needed; pointing towards an ear is useful only if the target and movement are understood. Check comfort, hearing, language and mobility when cooperation is difficult. 1

For acuity, ask the patient to read the indicated symbols, repeat an uncertain response and specify the last line or eye being tested. During refraction, “1 or 2?” compares lenses; clarify “clearer, worse or the same” and allow uncertainty rather than forcing a choice. Record the actual correction and whether acuity was measured with or without glasses; a conversational answer alone is not a standardised acuity measurement. 1

03Expand shorthand only as far as the findings permit

Internal dictation is a prompt for accurate documentation, not permission to invent a complete normal examination. The table preserves all 10 original entries and distinguishes description, uncertainty and interpretation. Clarify ambiguous “randständig” with the examiner; do not silently convert it to a sharp disc margin or proven perfusion. Record side, method and comparison with prior findings where relevant. 1

Expand shorthand only as far as the findings permit
Original shorthandMeaning and documentation limit
VAA reizfreiNo visible anterior inflammation in the examined structures; does not exclude every inflammatory condition
Medien klarAdequate media clarity for this examination; document view limits rather than infer a normal fundus
Cat. nuc./KernskleroseNuclear lens opacity/sclerosis; relate to symptoms and measured vision
Subcapsularis posteriorPosterior subcapsular cataract in posterior lens cortex anterior to posterior capsule, not behind capsule
Nachstar (NS)Posterior capsular opacification after lens surgery, distinct from posterior subcapsular cataract
Makula sauber/trockenNo observed exudation on the stated examination; does not automatically mean no drusen or all-normal macula
NHA anl.Retina attached within examined extent; state peripheral visibility and exclusions, not absolute proof against every tear
Papille vital, randständig, CDR 0.6Descriptive disc appearance; clarify ambiguous randständig. CDR 0.6 alone is not glaucoma or proof of perfusion
GKTVitreous opacities may explain floaters, but new symptoms require retinal assessment before reassurance
IOP R/L 13/15Right 13 mmHg, left 15 mmHg with method/time; neither a universal normal threshold nor every patient’s target

04Explain a diagnosis without promising an outcome

For cataract, explain lens clouding and its effect on symptoms before discussing surgery. The operation opens the anterior capsule and removes lens contents while usually retaining posterior capsular support for an intraocular lens. Multifocal lenses may reduce spectacle dependence but do not guarantee perfect near and distance vision; discuss suitability, optical trade-offs and alternatives. Posterior subcapsular cataract lies in the posterior lens cortex anterior to the capsule, not behind it. 1

Posterior capsular opacification after lens surgery is clouding of retained capsule, not a new cataract in the removed natural lens. Nd:YAG capsulotomy makes an opening when appropriately indicated; “simply laser it away” conceals pressure, inflammatory and retinal risks. Dry-eye treatment may include lubricants after evaluating the surface and alternatives; “only dryness” must not dismiss pain, photophobia or visual change. 1 4

Explain glaucoma as possible optic-nerve damage assessed with pressure, disc, fields and imaging, not as a single large cup or an “escalated nerve”. Explain AMD by its subtype and activity: “nothing can be done” is false as a general prognosis, and active neovascular disease may need treatment. New flashes can reflect vitreoretinal traction and require exclusion of tear/detachment; a plausible benign mechanism does not establish safety. 1

05Agree drops, spectacles and follow-up precisely

Name the prescribed medicine, eye, strength, frequency and duration, and ask how the patient actually uses it. If tapering is needed, give the individual written schedule and check understanding: the original “reduce every 5 days” is not a universal steroid or glaucoma-drop plan. “Continue drops” is incomplete without specifying which drops and the review point. 1

When progressive lenses are uncomfortable, check refraction, fitting, task and adaptation before suggesting alternatives such as separate distance and reading glasses. The original 2-glasses suggestion is an option, not the only solution. Follow-up in 1 year or 1–2 years may fit selected stable cases, not every diagnosis; document the individual reason, preparation for surgery when relevant and earlier-return instructions. 1

06Make reassurance conditional and confirm the plan

Reassure using the actual examination: “I have not found a tear in the examined retina today” is more informative than an absolute promise that nothing can happen. Explain the limits of the view and why new flashes, a shower of floaters, a fixed peripheral shadow or vision loss changes the plan. Tell the patient where and how urgently to seek help; do not require recurrence before assessing a concerning first episode. 1

Offer options and meaningful benefits, harms and uncertainty, then ask the patient to explain the agreed plan in their own words. Teach-back checks whether the explanation worked; it is not an examination of the patient. Handover should state findings, what remains uncertain, medicines, responsibility for the next step and warning symptoms so shorthand does not lose the safety net. 1 2 3

What are the main learning points?

Begin with the patient’s concern, translate descriptions into questions rather than diagnoses, document what was actually examined and confirm the treatment plan through teach-back. Reassurance must include its limits and a clear safety net.

When is assessment urgent?

New flashes, many new floaters, a fixed shadow/curtain or sudden visual/field loss requires urgent assessment. Severe pain, marked redness, photophobia or suspected infection also warrants urgent review, including after an injection or operation. Rapid visual loss, severe pain, marked inflammation, a pressure rise or suspected infection or neurological disease also needs urgent assessment.

References and access status

  1. 1
    Immutable original export; clinical dialogue/teaching examples; no authenticated patient transcript

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    NICE NG197: shared decision making

    Selected official sections 1.2.7–1.2.14 and teach-back/risk discussion text read 15 November 2026; not whole guideline or trial appraisal.

  3. 3
    WHO: communication during patient handovers

    Historical selected access recorded in review 060 on 9 November 2026 reused; not independently retrieved in full for 140. Exact applicable clinical/source limits remain pending.

  4. 4
    AAO: posterior capsulotomy and patient risk information

    Historical selected access recorded in review 060 on 9 November 2026 reused; not independently retrieved in full for 140. Exact applicable clinical/source limits remain pending.

  5. 5
    EGS: target IOP treatment principles, historical fourth edition

    Historical selected access recorded in review 060 on 9 November 2026 reused; not independently retrieved in full for 140. Exact applicable clinical/source limits remain pending.

  6. 6
    UK diabetic eye screening: people who drive, updated 2024

    Historical selected access recorded in review 060 on 9 November 2026 reused; not independently retrieved in full for 140. Exact applicable clinical/source limits remain pending.